As of May 26
| -2.43 / -4.99%|
The 13 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 68.00, with a high estimate of 130.00 and a low estimate of 60.00. The median estimate represents a +47.12% increase from the last price of 46.22.
The current consensus among 14 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.